StockData
Longeveron Inc. logo

Longeveron Inc. (LGVN) stock

LGVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$1.92−0.19 (-9.00%)

Close on Nov 18, 2026Market cap $61.21MP/E –Yield –

Longeveron ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Longeveron's ebitda for the twelve months ending Jun 30, 2026 was -$22.86M. For fiscal 2025 it was -$22.49M. The highest annual figure on record is -$3.78M in fiscal 2020.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$22.49M–
FY2024Dec 31, 2024-$15.82M–
FY2023Dec 31, 2023-$20.33M–
FY2022Dec 31, 2022-$17.34M–
FY2021Dec 31, 2021-$17.46M–
FY2020Dec 31, 2020-$3.78M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$5.97M–
Q1 FY2026Mar 31, 2026-$4.58M–
Q4 FY2025Dec 31, 2025-$5.20M–
Q3 FY2025Sep 30, 2025-$7.11M–
Q2 FY2025Jun 30, 2025-$5.20M–
Q1 FY2025Mar 31, 2025-$4.98M–
Q4 FY2024Dec 31, 2024-$4.08M–
Q3 FY2024Sep 30, 2024-$4.45M–
Q2 FY2024Jun 30, 2024-$3.30M–
Q1 FY2024Mar 31, 2024-$3.89M–
Q4 FY2023Dec 31, 2023-$5.45M–
Q3 FY2023Sep 30, 2023-$4.96M–
Q2 FY2023Jun 30, 2023-$5.51M–
Q1 FY2023Mar 31, 2023-$4.52M–
Q2 FY2022Jun 30, 2022-$4.02M–
Q1 FY2022Mar 31, 2022-$3.29M–
Q4 FY2021Dec 31, 2021-$4.53M–
Q3 FY2021Sep 30, 2021-$4.71M–
Q2 FY2021Jun 30, 2021-$4.96M–
Q1 FY2021Mar 31, 2021-$3.26M–
Q4 FY2020Dec 31, 2020-$1.97M–
Q3 FY2020Sep 30, 2020-$760.00K–
Q2 FY2020Jun 30, 2020-$1.03M–
Q1 FY2020Mar 31, 2020-$13.00K–

More Longeveron figures

See a number that looks wrong?